Evidence map›Paper›PMID 29224367›Full record

ArticleCurrent medical research and opinion2018

Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis.

Kenji Oritani, Kohshi Ohishi, Shinichiro Okamoto, Keita Kirito, Norio Komatsu, Tetsuzo Tauchi, Hiroshi Handa, Shigeki Saito, Katsuto Takenaka, Kazuya Shimoda and 5 more

2 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in Current medical research and opinion, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01392443 phase2completednot on this map

A Multi-national Open-label Phase II Study of the JAK Inhibitor INC424 in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis

TypeinterventionalSponsorNovartis PharmaceuticalsRan2010 to 2017Enrolled120ConditionsPrimary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Post-Essential Thrombocythemia (ET) MFArmsRuxolitinib
NCT02087059 phase3completednot on this map

A Multicenter, Open-label Clinical Study of the JAK Inhibitor Ruxolitinib (INC424) in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis

TypeinterventionalSponsorNovartis PharmaceuticalsRan2014 to 2015Enrolled51ConditionsPrimary Myelofibrosis (MF)ArmsRuxolitinib
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 13 institutions in 1 country.

Kenji Oritania Department of Hematology, Graduate School of Medical Sciences , International University of Health and Welfare Hospital , Tochigi , Japan.
Kohshi Ohishib Blood Transfusion Service, Mie University Hospital , Mie , Japan.
Shinichiro Okamotoc Division of Hematology, Department of Medicine , Keio University Hospital , Tokyo , Japan.
Keita Kiritod Department of Hematology/Oncology , University of Yamanashi , Yamanashi , Japan.
Norio Komatsue Department of Hematology , Juntendo University School of Medicine , Tokyo , Japan.
Tetsuzo Tauchif Department of Hematology , Tokyo Medical University , Tokyo , Japan.
Hiroshi Handag Department of Medicine , Gunma University Hospital , Gunma , Japan.
Shigeki Saitoh Department of Hematology , Nagoya University Hospital , Nagoya , Japan.
Katsuto Takenakaj Center for Cellular and Molecular Medicine, Kyushu University Hospital , Japan.
Kazuya Shimodak Gastroenterology and Hematology , University of Miyazaki , Miyazaki , Japan.
Hikaru Okadal Department of Medical Affairs-Oncology , Novartis Pharma KK , Tokyo , Japan.
Taro Amagasakim Clinical Development, Japan Integrated Biostatistics, Novartis Pharma KK , Tokyo , Japan.
Shiho Wakasen Department of Commercial Excellence-Oncology , Novartis Pharma KK , Tokyo , Japan.
Kojiro Shimozumao Department of Biomedical Sciences , Ritsumeikan University , Shiga , Japan.
Koichi Akaship Department of Medicine and Biosystemic Sciences , Kyushu University , Fukuoka , Japan.
Novartis (Japan) · JPGunma University Hospital · JPInternational University of Health and Welfare · JPJuntendo University · JPKeio University Hospital · JPKyushu University · JPKyushu University Hospital · JPMie University Hospital · JPNagoya University Hospital · JPRitsumeikan University · JPTokyo Medical University · JPUniversity of Miyazaki · JPUniversity of Yamanashi · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesMyelofibrosis (MF) is associated with a significant symptom burden that severely impacts patient quality-of-life (QoL). Ruxolitinib, a potent Janus kinase 1 (JAK1)/JAK2 inhibitor, led to substantial improvements in splenomegaly, MF-associated symptoms, and QoL in the phase 3 COMFORT studies, proving superior to placebo and best available therapy. This study evaluated the effect of ruxolitinib on symptoms and QoL in Japanese patients with MF.

methodsA pooled analysis of studies A2202 (NCT01392443) and AJP01 (NCT02087059) of ruxolitinib in Japanese patients with MF (n = 81) was conducted. Changes in total symptom score (TSS) and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 were summarized.

resultsMost patients received a starting dose of 15 or 20 mg twice daily (BID) and had a final titrated dose of ≥10 mg BID. Overall, 67.7% (44/65) achieved a ≥50% reduction from baseline in TSS at week 24. Reductions in TSS were seen in every dose group; the greatest reductions occurred in patients with a final titrated dose of 20 or 25 mg BID. Improvements in QoL were seen in patients who achieved a ≥50% reduction in TSS. Generally, improvements in TSS and individual symptoms correlated with reductions in spleen size, with those having a ≥35% reduction in spleen volume having the greatest improvements.

conclusionsConsistent with COMFORT-I, ruxolitinib provided substantial improvements in symptoms and QoL in Japanese patients with MF, with higher doses of ruxolitinib associated with better responses.

Indexed as

Quality of LifeAdultAgedAged, 80 and overFemaleHumansJanus Kinase 2MaleMiddle AgedNitrilesPrimary MyelofibrosisProtein Kinase InhibitorsPyrazolesPyrimidinesTreatment OutcomeJAK2 protein, humanJanus Kinase 2NitrilesProtein Kinase InhibitorsPyrazolesPyrimidinesruxolitinibJapaneseMyelofibrosisQuality-of-lifeRuxolitinib

Identifiers

PMID29224367
OpenAlexW2772311550

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.